¼Óº¸
VIP
ÅëÇÕ°Ë»ö

¼¿¸®¹ö¸®, ¾Æ½Ã¾Æ ÃÖ´ë ºñÁö´Ï½º ÆÄÆ®³Ê¸µ '¹ÙÀÌ¿ÀÀçÆÒ'¼­ ±Û·Î¹ú Á¦¾à»ç 10¿©°÷°ú ´Üµ¶ ¹ÌÆÃ

  • Á¤Èñ¿µ MTN±âÀÚ
  • Ä«Ä«¿ÀÅå °øÀ¯Çϱâ
  • Ä«Ä«¿ÀÅå ³ª¿¡°Ô Àü¼ÛÇϱâ
  • ÆäÀ̽ººÏ
  • Æ®À§ÅÍ
  • ³×À̹ö
  • ÅÚ·¹±×·¥
  • ¹®ÀÚ
  • 2020.10.16 14:36
  • ±ÛÀÚÅ©±âÁ¶Àý


¼¿¸®¹ö¸® (6,680¿ø ¡å2,850 -29.91%)´Â 14ÀϺÎÅÍ ¿Â¶óÀÎ ¹× ´ë¸éÀ¸·Î ÁøÇàµÇ´Â ¾Æ½Ã¾Æ ÃÖ´ë±Ô¸ð ¹ÙÀÌ¿À ÆÄÆ®³Ê¸µ Çà»çÀÎ ¹ÙÀÌ¿ÀÁ¦ÆÒ ÄÁÆÛ·±½º(Bio-Japan)¿¡ Âü°¡ÇØ ±Û·Î¹ú Á¦¾à»çµé¿¡°Ô ÃֽŠ¿¬±¸?°³¹ß µ¥ÀÌÅ͸¦ Á¦½ÃÇÏ°í TSDT Ç÷§Æû±â¼ú ¹× ½Å¾àÈĺ¸¹°Áú¿¡ ´ëÇÑ °øµ¿¿¬±¸, °øµ¿°³¹ß ¹× ¶óÀ̼¾½Ì ºñÁî´Ï½º¸¦ ÃßÁøÇß´Ù°í 16ÀÏ ¹àÇû´Ù.

ÀÌ Çà»ç´Â ¹Ì±¹, À¯·´, ÀϺ» µîÀÇ ´Ù±¹Àû Á¦¾à»çµéÀÇ °íÀ§ ÀÓ¿øµéÀÌ ´ë°Å Âü¼®ÇØ ½Å¾àÈĺ¸¹°ÁúµéÀÇ ¶óÀ̼¾½Ì ÀÎ, ¶óÀ̼¾½Ì ¾Æ¿ôÀ» Æ÷ÇÔÇØ Ç÷§Æû±â¼úÀÇ ±â¼úÀÌÀü µî¿¡ ´ëÇÑ ºñÁö´Ï½º°¡ ºü¸£°Ô ÁøÇàµÇ´Â ¾Æ½Ã¾Æ ÃÖ´ë ¹ÙÀÌ¿À Á¦¾à¾÷°èÀÇ ¿¬·Ê Çà»ç´Ù. ¿ÃÇØ´Â ¿Â¶óÀÎÀ¸·Îµµ ÇÔ²² ÁøÇàµÅ ´õ¿í ÀÇ»ç°áÁ¤ ±ÇÇÑÀÌ ÀÖ´Â °íÀ§ ÀÓ¿ø±ÞÀÇ Âü¼®ÀÌ µÎµå·¯Á³´Ù.

¼¿¸®¹ö¸®´Â À̹ø ÄÁÆÛ·±½º¿¡¼­ ¹Ì±¹ÀÇ È­ÀÌÀÚ(Pfizer), µ§¸¶Å©ÀÇ ·¹¿ÀÆĸ¶(Leo Pharma)¿Í ·±µåº¤(Lundbeck), µ¶ÀÏÀÇ º£¸µ°ÅÀ×°ÖÇÏÀÓ(Boehringer Ingelheim), ÀϺ»ÀÇ ÀϺ»½Å¾à(Nippon Shinyaku), ¿ÀÃ÷Ä«Á¦¾à(Otsutka Pharmaceutical), ½ºÅÚ¶óÁ¦¾à(Stellas Pharmaceutical), ½ºÆäÀÎÀÇ Áö³×ÀÌ·ÎÁ¦¾à(Zinereo Pharma) µî ±Û·Î¹ú Á¦¾à»çµé°ú ÆÄÆ®³Ê¸µ ¹ÌÆÃÀ» °¡Á³´Ù°í ¹àÇû´Ù.

À̹ø ¹ÌÆÿ¡¼­ ¼¿¸®¹ö¸®ÀÇ ÃֽŠ¿¬±¸ µ¥ÀÌÅÍ¿¡ ´ëÇØ È­ÀÌÀÚ (¼¼°è3À§) ´ëÇ¥·Î Âü¿©ÇÑ ¾Æ½Ã¾ÆÃÑ°ý ÀÌ»ç(Senior Director)´Â TSDT Ç÷§Æû±â¼ú¿¡ ´ëÇØ "¸Å¿ì ³î¶ó¿î ±â¼ú(This technology is very impressive. Amazing.)¡± À̶ó°í ¹àÈ÷¸ç, "¼¿¸®¹ö¸®ÀÇ ±â¼úÀº È­ÀÌÀÚ°¡ ÇöÀç °¡Àå Å« °ü½ÉÀ» °¡Áö°í ÀÖ´Â Èñ±Íº´(rare disease) ¹× ³­Ä¡º´(orphan disease) ºÐ¾ß¿¡¼­ ±²ÀåÈ÷ À¯¿ëÇÒ °Í¡± À̶ó°í ¸»Çß´Ù.

±×´Â "Ãß°¡ ¹ÌÆÃÀ»Áï½Ã °®°í,ÀÌ ºÐ¾ß¿¡¼­ ¼¿¸®¹ö¸®¿Í ±â¼úÇù·Â ¹× »ç¾÷ÀûÀÎ Çù¾÷À» ¸Î±â¸¦ Èñ¸ÁÇÑ´Ù(We are very keen on starting a scientific and business partnership with Cellivery in the near future on the shared fields)"°í Á¦¾ÈÇß´Ù.

·¹¿ÀÆĸ¶ÀÇ ¾Æ½Ã¾ÆÃÑ°ý ºÎ»çÀå (VP)Àº "TSDT Ç÷§Æû±â¼úÀ» »ç¿ëÇϸé ÇöÀç ½ÃÆÇÁßÀÎ ÇǺκ´ Ä¡·áÁ¦µéÀÇ ÇǺÎÀü¼Û È¿À²¼ºÀ» ³ôÀ̴µ¥ ¾öû³­ µµ¿ò(radically improve)ÀÌ µÉ °Í (We believe application of TSDT platform could radically improve the delivery efficacy of existing skin disease drugs)¡± À̶ó°í ÀÇ°ßÀ» ¹àÇûÀ¸¸ç, ÇöÀç ·¹¿ÀÆĸ¶°¡ ¼¼°è½ÃÀå¿¡ ÆǸÅÇÏ°í ÀÖ´Â ¾à¹°µé°ú °³¹ßÁßÀÎ ÀÓ»óÈĺ¸¹°Áúµé¿¡ ´ëÇÑ TSDT Ç÷§Æû±â¼úÀÇ µµÀÔÀ» °ËÅäÇϱâ À§ÇØ ¹ÙÀÌ¿ÀÀçÆÒ Çà»ç°¡ ³¡³ª°í ÈÄ¼Ó ¹ÌÆÃÀ» ´ÙÀ½´Þ Áß¿¡ Çѱ¹¿¡¼­ ÁøÇàÇϱâ·Î Çß´Ù. µ¡ºÙ¿©, ¼¿¸®¹ö¸®°¡ ÇöÀç Äڷγª19 Ä¡·áÁ¦·Î °³¹ßÇÏ°í ÀÖ´Â Ç×¹ÙÀÌ·¯½º/Ç׿°Áõ ¸é¿ªÄ¡·áÁ¦ iCP-NIÀÇ ¿¬°íÁ¦Çüûù¸¦ ÅëÇÑ ¾ÆÅäÇÇ ÇǺο° ÀûÀÀÁõ È®´ë¿¡µµ Å« °ü½ÉÀ» º¸À̸ç, iCP-NI¿¡ ´ëÇÑ ¸ðµç ÀÚ·á¿Í ÇÔ²² °øµ¿°³¹ß ¹× ¶óÀ̼¾½Ì¿¡ ´ëÇÑ ³íÀǸ¦ Á¶±â¿¡ ÁøÇàÇϱâ·Î Çß´Ù°í ¹àÇû´Ù.

¶Ç ³ú½Å°æ°èÁúȯ Àü¹®ÀÎ ·±µåº¤À» ´ë»óÀ¸·Î ÅðÇ༺³úÁúȯġ·á½Å¾à iCP-ParkinÀÇ Ä¡¸Å ¹× ¾ËÃ÷ÇÏÀ̸Ӻ´¿¡ ´ëÇÑ »õ·Î¿î Ä¡·áÈ¿´É µ¥ÀÌÅ͸¦¹ßÇ¥ ÇßÀ¸¸ç, ·±µåº¤ÀÇ »ç¾÷°³¹ß °í¹®Àº¾Æ¹Ð·ÎÀÌµå º£Å¸ (A¥â)´Ü¹éÁúÀÇ ³úÁ¶Á÷ ħÂøÀ¸·Î ¹ßº´µÇ´Â ¾ËÃ÷ÇÏÀ̸Ӻ´µ¿¹°¸ðµ¨¿¡¼­ ´ëÁ¶±º ´ëºñ 101%ÀÇ ÀÎÁö±â´É(cognitive function)ȸº¹È¿´ÉÀ» º¸ÀÎ iCP-ParkinÀÇ Ä¡¸Å Ä¡·áÈ¿´É¿¡ ´ëÇØ "iCP-ParkinÀÌ ÆÄŲ½¼º´ »Ó¸¸ ¾Æ´Ï¶ó, ¾ËÃ÷ÇÏÀÌ¸Ó º´¿¡¼­µµ ³î¶ó¿î È¿´ÉÀ» º¸ÀδÙ(iCP-Parkin¡¯s effects are only shown not in Parkinson¡¯s disease, but even more extensively in Alzheimer¡¯s)¡± ¶ó°í ¹àÈ÷¸ç, Â÷ÁÖ¿¡ ºñ´ë¸éÀ¸·Î ÁøÇàµÉ ¹ÙÀÌ¿À À¯·´ (Bio-EU) Çà»ç¿¡¼­ ´Ù½Ã ¸¸³ª ±¸Ã¼ÀûÀÎ »ç¾÷°èȹÀ» ³íÀÇ ÇÏÀÚ°í Á¦¾È ÇßÀ½À» ¹àÇû´Ù.

¼¿¸®¹ö¸®´Â º£¸µ°ÅÀΰÖÇÏÀÓÀÇ »ç¾÷°³¹ß ÀÓ¿ø°úµµ ¹ÌÆÃÀ» °¡Á³À¸¸ç, ÀÌ´Â ÀÌ¹Ì ¼¿¸®¹ö¸®¿Í °øµ¿¿¬±¸ ¹× ¶óÀ̼¾½ÌÇù»óÀ» ÁøÇàÇÏ°í ÀÖ´Â µ¶ÀÏ º£¸µ°ÅÀ×°ÖÇÏÀÓÀÇ ºÎ¼­¿Í´Â º°°³ÀÇ, Ãß°¡ÀûÀÎ ºñÁö´Ï½º Çù¾÷¿¡ ´ëÇÑ È¸ÀÇ¿´´Ù°í ¼¿¸®¹ö¸®Ãø »ç¾÷°³¹ß °ü°èÀÚ´Â ¹àÇû´Ù. º£¸µ°ÅÀΰÖÇÏÀÓÀº¼¿¸®¹ö¸®ÀÇTSDT Ç÷§Æû±â¼úÀ» ÅëÇØ ÀÚ»çÀÇ ÁÖ¿ä Áúº´ºÐ¾ßÀÎ ÁßÃ߽Űæ°è(CNS), Èñ±ÍÁúº´(rare disease), ¸®¼Ò¼ØÃàÀûº´(LSD) ºÐ¾ßÀÇ ¿¬±¸, »ç¾÷Àû È®ÀåÀ» ±â´ëÇÑ´Ù°í ¹àÇûÀ¸¸ç,¡°¾ç»ç°£ »óÈ£ ÀÌÀÍÀÌ µÇ´Â Àü·«Àû Á¦ÈÞ¸¦ ¼º»ç½ÃÅ°´Âµ¥ ÀÖ¾î Ãâ¹ßÁ¡À» ½ÃÀÛÇÏ¿© ±â»Ú´Ù (We are glad to mark the start of a strategical alliance mutually benefiting both parties.)¡±¸ç ±¸Ã¼ÀûÀÎ ±â¼úÀû ¹ÌÆÃÀ» ÁøÇàÇϱâ·Î ÇÏ¿´´Ù.

¼¿¸®¹ö¸®ÀÇÁ¶´ë¿õ ´ëÇ¥´Â ¡°¹ÙÀÌ¿ÀÀçÆÒ°ú °°Àº ¼¼°èÀûÀÎ Çà»ç´Â ´ÙÄÉ´Ù,´ÙÀÌÀÌÄ¡»êÄìµî°ú óÀ½ ¹ÌÆÃÇؼ­ Áö±Ý±îÁö Çù¾÷¿¡ À̸£°í ÀÖ´Â ¸Å¿ì Áß¿äÇÑ ºñÁî´Ï½º È°µ¿¹«´ëÀÌ´Ù. ¿ÃÇØ´Â ¿¹»óÄ¡ ¸øÇÏ°Ô Äڷγª19·Î ÀÎÇØ °ø°ÝÀûÀ¸·Î ÁøÇàÇÏ´ø ÇØ¿Ü ÇÐȸ Âü°¡ ¹× ºñÁî´Ï½º ¹æ¹®¿¡ ¸¹Àº Â÷ÁúÀÌ ÀÖ¾ú°í, ÁøÇàµÇ°í ÀÖ´ø ÀϺ», ¹Ì±¹¿¡¼­ÀÇ °øµ¿°³¹ßµéµµ ±×µé ¿¬±¸¼ÒµéÀÇ Æó¼â ¹× ÀçÅñٹ«·Î, ±âÁ¸ ¿¹»ó ½Ã±âº¸´Ù ¸¹ÀÌ Áö¿¬µÇ¾ú´Ù. ÀÌ¿¡ ¸÷½Ã ¾ÈŸ±õÁö¸¸, Á¡Â÷ Á¤»ó±Ëµµ·Î ȸº¹µÇ°í ÀÖ¾î ´ÙÇàÀ̶ó »ý°¢ÇÑ´Ù. ÃÖ´ëÇÑ »¡¸®, À̸£¸é ´ÙÀ½´Þ Áß ±â¾÷ÀΠƯº°ÀÔ±¹ÀýÂ÷·Î ÀϺ»¿¡ °¡¼­ ´ÙÄÉ´Ù ¹× ´ÙÀÌÀÌÄ¡»êÄì µî°ú ÇöÀç ÁøÇàµÇ´Â °øµ¿¿¬±¸¿Í º»°ÝÀûÀÎ ¶óÀ̼¾½Ì ¼º»ç¸¦ À§ÇØ ±¸Ã¼ÀûÀ¸·Î ³íÀÇÇÒ °ÍÀÌ´Ù¡± ¶ó°í ¹àÇû´Ù.


Á¤Èñ¿µ ¸Ó´ÏÅõµ¥À̹æ¼Û MTN ±âÀÚ



¸Ó´ÏÅõµ¥ÀÌ ÁÖ¿ä´º½º

"8¸¸ÀüÀÚ Âï°í ´õ °£´Ù" °³¹Ìµé ȯȣ¡¦ÄÚ½ºÇÇ 2800¼± ³Ñ±æ±î
³×À̹ö ¸ÞÀο¡¼­ ¸Ó´ÏÅõµ¥ÀÌ ±¸µ¶ Ä«Ä«¿ÀÅå¿¡¼­ ¸Ó´ÏÅõµ¥ÀÌ Ã¤³Î Ãß°¡

º£½ºÆ®Å¬¸¯

¿À´ÃÀÇ ²ÜÆÁ

  • ´º½º ¼Ó ¿À´Ã
  • ´õ¿µ»ó
  • ³¯¾¾´Â?
  • ÇコÅõµ¥ÀÌ

¸¹ÀÌ º» ´º½º

ºÎµ¿»ê À¯Æ©ºê Á¤º¸Ã¤³Î ºÎ¸´Áö
2023 ´ëÇѹα¹ »çȸ¾ÈÀüÁö¼ö

Æ÷Åä / ¿µ»ó